MedTrace Logo

GSK1265744 (Cabotegravir, CAB) for Named Patient/Compassionate Use in HIV

NCT03462810 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2021-05-21

No results posted yet for this study

Summary

The goal of this compassionate use program is to provide a mechanism to supply Cabotegravir, CAB on an individual named patient basis for treatment of individuals who have no available treatment alternatives and/or limited treatment options (e.g., who are unable to participate in the Phase III clinical studies or do not qualify), and are in need of new drugs to construct an effective antiviral regimen and may require the use of parenterally administered drug given underlying medical conditions. You can access ViiV's Policy on Compassionate via https://us.viivhealthcare.com/media/124424/viivs-external-policy-on-cup\_final-version\_23feb2017.pdf.

Conditions

  • Infection, Human Immunodeficiency Virus

Interventions

DRUG

cabotegravir, CAB

open label investigational product

Sponsors & Collaborators

  • ViiV Healthcare

    lead INDUSTRY

Principal Investigators

  • GSK Clinical Trials · ViiV Healthcare

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03462810 on ClinicalTrials.gov